Brief: Shanghai Junshi Biosciences Updates On License And Commercialization Agreement With Coherus

Coherus Oncology

10/01/2024 14:58

Jan 10 (Reuters) - Shanghai Junshi Biosciences Co Ltd
 688180.SS :
    * UPDATE ON LICENSE AND COMMERCIALIZATION AGREEMENT WITH
COHERUS
    * RECEIVED A LETTER FROM COHERUS
    * LETTER NOTIFYING COMPANY OF ITS INTENTION TO TERMINATE
COOPERATION BETWEEN COMPANY AND COHERUS
    * TERMINATE COOPERATION COHERUS WITH RESPECT TO RECOMBINANT
HUMANIZED MONOCLONAL ANTIBODY AGAINST TIGIT
    * ONCE TERMINATION BECOMES EFFECTIVE LICENSE RIGHTS OF
COHERUS IN
RESPECT OF JS006 WILL BE TERMINATED
    * COMPANY WILL REGAIN ALL GLOBAL RIGHTS TO DEVELOP,
MANUFACTURE
AND COMMERCIALIZE JS006.
    * TERMINATION WILL NOT AFFECT EXERCISE PAYMENT OF US$35
MILLION

Further company coverage:  688180.SS 

 ((Reuters.Briefs@thomsonreuters.com;))